Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders... Show more
Bristol Myers Squibb shares have consolidated in recent weeks even as the company's fundamentals strengthened. After rallying through the spring and summer, the stock pulled back from roughly the high-$60s into the low-$60s, reflecting profit-taking and broader sector rotation rather than a deterioration in the underlying business. The shares still carry a forward price-to-earnings multiple near 9, well below many large-cap pharmaceutical peers, a valuation discount that has drawn renewed attention from analysts arguing the market has yet to fully price in the company's newer therapies.
Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing, and commercializing medicines across oncology, hematology, immunology, cardiovascular disease, and neuroscience. Its portfolio includes blockbuster therapies such as Opdivo and Eliquis, the latter co-marketed with Pfizer (PFE), alongside a fast-growing group of newer products including Camzyos, Reblozyl, Breyanzi, Opdualag, Sotyktu, Zeposia, and Cobenfy. The company's acquisition of Celgene and a steady cadence of pipeline partnerships and bolt-on deals have broadened its late-stage pipeline and positioned it to manage patent expirations on legacy brands through portfolio renewal.
Second-quarter 2026 results were a central catalyst. Total revenue reached $12.97 billion, up 6% year over year, while non-GAAP EPS of $2.04 came in ahead of consensus. The Growth Portfolio rose 15% to $7.6 billion, driven by Reblozyl, Camzyos, Breyanzi, and Opdivo Qvantig, and management raised its full-year revenue outlook to approximately $49–50 billion and non-GAAP EPS guidance to $6.75–$7.00. The company also lifted its 2026 Eliquis growth expectation to 20%–25%.
The board declared a quarterly dividend of $0.63 per share, payable November 2, 2026, to shareholders of record as of October 2, 2026, continuing a 17-year streak of dividend increases. In mid-September 2026, the company reported positive two-year Phase 3 data for Sotyktu in psoriatic arthritis, reinforcing its immunology pipeline, and Piper Sandler reiterated an Overweight rating on the shares. Reports of exploratory merger discussions with AstraZeneca (AZN) also circulated, though no transaction has been confirmed. The average analyst price target near $66.71 sits above recent trading levels.
Tickeron's Trending AI Robots page curates a selection of the platform's most relevant automated trading bots from a library of hundreds of strategies trading thousands of tickers. Rather than listing every available bot, this section highlights only top-performing and currently relevant bots, each of which varies in strategy, timeframe, and performance metrics. The page allows traders to compare approaches and monitor bots that align with their own objectives, from short-term momentum strategies to longer-horizon models. Investors interested in systematic, data-driven approaches to the market can explore the curated list to see which strategies are currently capturing attention.
Looking ahead, investors will monitor third-quarter results on October 29, 2026, for confirmation that Growth Portfolio momentum and Eliquis strength continue. Key pipeline catalysts include late-stage readouts for the blood thinner milvexian, now expected in early 2027, as well as regulatory decisions on iberdomide and mezigdomide and the ongoing ADEPT program for Cobenfy in Alzheimer's-related psychosis. The company has signaled it could launch more than 10 new medicines by the end of the decade, a goal that underpins the bull case for offsetting generic competition. Principal risks include continued erosion in the legacy portfolio, drug-pricing pressure and regulatory scrutiny, clinical trial timing, and competitive dynamics in oncology and immunology. These factors, along with the sustainability of the dividend and free cash flow generation, will shape investor sentiment into 2026 and beyond.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
BMY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 23 of 35 cases where BMY's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 66%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMY advanced for three days, in 172 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
The 10-day RSI Indicator for BMY moved out of overbought territory on August 20, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 18 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 55%.
The Momentum Indicator moved below the 0 level on September 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BMY as a result. In 49 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 54%.
The Moving Average Convergence Divergence Histogram (MACD) for BMY turned negative on August 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 22 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 45%.
BMY moved below its 50-day moving average on September 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BMY crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 53%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 53%.
The Aroon Indicator for BMY entered a downward trend on September 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is 22 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.770) is normal, around the industry mean (19.050). P/E Ratio (13.890) is within average values for comparable stocks, (34.258). BMY's Projected Growth (PEG Ratio) (17.558) is slightly higher than the industry average of (5.614). Dividend Yield (0.040) settles around the average of (0.025) among similar stocks. P/S Ratio (2.642) is also within normal values, averaging (4.033).
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. BMY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 85 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 63, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of pharmaceuticals products
Industry PharmaceuticalsMajor